SLC2A1 and melanoma: To get further insight into the perspective of potential clinical GLUT1 inhibitory strategies, we applied WZB117, a new, highly specific small-molecule inhibitor of GLUT1 [25], to the human melanoma cell lines WM3211, Mel-Im and SbCl2 in vitro.